Revance Therapeutics, Inc. Annual Operating Lease, Payments in USD from 2019 to 2023

Taxonomy & unit
us-gaap: USD
Description
Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.
Summary
Revance Therapeutics, Inc. quarterly/annual Operating Lease, Payments history and growth rate from 2019 to 2023.
  • Revance Therapeutics, Inc. Operating Lease, Payments for the quarter ending March 31, 2024 was $2.56M, a 22.6% increase year-over-year.
  • Revance Therapeutics, Inc. annual Operating Lease, Payments for 2023 was $12.1M, a 45.2% increase from 2022.
  • Revance Therapeutics, Inc. annual Operating Lease, Payments for 2022 was $8.32M, a 20% decline from 2021.
  • Revance Therapeutics, Inc. annual Operating Lease, Payments for 2021 was $10.4M, a 53.2% increase from 2020.
Operating Lease, Payments, Annual (USD)
Operating Lease, Payments, YoY Annual Growth (%)
Period Value YoY Chg Change % Start Date End Date Report Filed
2023 $12.1M +$3.76M +45.2% Jan 1, 2023 Dec 31, 2023 10-K 2024-02-28
2022 $8.32M -$2.09M -20% Jan 1, 2022 Dec 31, 2022 10-K 2024-02-28
2021 $10.4M +$3.62M +53.2% Jan 1, 2021 Dec 31, 2021 10-K 2024-02-28
2020 $6.79M +$451K +7.12% Jan 1, 2020 Dec 31, 2020 10-K 2023-02-28
2019 $6.34M Jan 1, 2019 Dec 31, 2019 10-K 2022-02-28
* An asterisk sign (*) next to the value indicates that the value is likely invalid.